SCHEMBL14920908

SCHEMBL14920908

N#Cc1cccc(S(=O)(=O)NCC(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.48
ACLY P53396 2/20 0.47
PGR P06401 1/20 0.47
CYP19A1 P11511 1/20 0.47
RORC P51449 1/20 0.46
GLO1 Q04760 1/20 0.45
SLC40A1 Q9NP59 1/20 0.45
SLC22A12 Q96S37 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
IDH2 P48735 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NR1H3 Q13133 1/20 0.43
S1PR1 P21453 1/20 0.42
TRIM24 O15164 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
PNMT P11086 1/20 0.41
PTGES2 Q9H7Z7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4615617 0.80 PGR (0.50) KAT6AACLYPGRCYP19A1GLO1
SCHEMBL12481561 0.78 CYP2C19 (0.58) KAT6AACLYPGRCYP19A1GLO1
SCHEMBL12953965 0.78 KMT2A (0.51) KAT6AACLYPGRCYP19A1GLO1
SCHEMBL7978280 0.77 ATM (0.56) KAT6APGRIDH2TDP1MAPK1
SCHEMBL5032650 0.77 CYP19A1 (0.60) CYP19A1IDH2TDP1MAPK1PNMT
SCHEMBL4019035 0.77 CYP19A1 (0.65) ACLYPGRCYP19A1
SCHEMBL3528919 0.76 CYP2C19 (0.57) IDH2
SCHEMBL5332920 0.75 PGR (0.46) KAT6AACLYPGRCYP19A1GLO1
SCHEMBL5785004 0.75 KDM4E (0.52) KAT6AACLYPGRCYP19A1GLO1
SCHEMBL15653259 0.75 IDH2 (0.44) IDH2TDP1MAPK1PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630929-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2017-04-25 US disclosed
US-20140296245-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS, INC. (CA) 2014-10-02 US disclosed
EP-2773637-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2014-09-10 EP disclosed
WO-2013064983-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296245-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS TRPV1, TRPA1, TRPV3 KAT6A 4380/4885ACLY 3421/4885PGR 4072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.